Introduction {#Sec1}
============

*Staphylococcus aureus* (*S. aureus*), which is normally presented in the microbiota of the human skin and is generally asymptomatic. It remains one of the most common drug-resistant pathogens that causes infection in hospitalized patients \[[@CR1], [@CR2]\]. Investments in infection reduction have been posed in intensive care units, which has been defined as an "epicenter" of nosocomial infections, by measurements of skin decolonization involving daily chlorhexidine bathing \[[@CR3]\]. The practice was adopted because of evidence that universal decolonization reduces device-associated bacteremia, all-cause bacteremia, and multidrug-resistant organisms \[[@CR3], [@CR4]\]. However, the nasal carriage is also unavoidable for endogenous infections and for transmission to other individuals, as the colonization of extra nasal sites often originates from the nasal reservoir \[[@CR5]\]. *S. aureus* nasal carriage has been extensively studied by numerous studies, as it was the most common pathogen associated with a postoperative surgical site infections (SSIs), what remains unclear is the exact source of the pathogen \[[@CR6]\].

It has been shown that being a nasal carrier of *S. aureus* is a significant risk factor for developing a SSI \[[@CR7]\]. In this regard, it seems that the number of SSIs acquired in hospitals may be reduced by decolonization of nasal *S. aureus* carriage on admission \[[@CR8]\]. Special attention was paid to nasal decontamination for prevention of SSIs in *S. aureus* carriers. The results of several RCTs in different hospitals and institutions are still mixed and inconclusive, limited by the population and surgery form \[[@CR6], [@CR9]\]. The aim of the study is to evaluate the use of nasal decontamination in different types of surgery and provide some evidence that makes efforts to measure of infection control and prevention.

Methods {#Sec2}
=======

This study was performed in accordance with the guideline of Preferred Reporting Items for Systematic Reviews and Meta Analyses \[[@CR10]\] and Cochrane's Handbook \[[@CR11]\] guidelines. A prospective protocol was registered in advance and uploaded to the PROSPERO online platform. The registration number is CRD42020170139.

Literature search {#Sec3}
-----------------

We searched English literature in PubMed, Embase, Web of science, and the Cochrane Library using combinations of the following terms: (1)Nasal or Nose; (2) *Staphylococcus aureus*; (3) Mupirocin or Chlorhexidine or Decontamination. We limited the search to human studies published in randomized trials. All databases were searched from the date of inception up to 20 December 2019. The search strategy used in PubMed is shown in Additional file [1](#MOESM1){ref-type="media"}: Appendix S1.

Eligibility criteria {#Sec4}
--------------------

Studies were eligible for this review if they met the following criteria: (1) a randomized controlled trial of human; (2) had to describe the standard microbial isolation and identification, like *S. aureus*, MRSA or MSSA; (3) included patients scheduled for surgery without infectious diseases. Reviews, case reports, conference abstracts, animal experiments, letters, editorials and studies without randomization were excluded.

Data extraction and quality evaluation {#Sec5}
--------------------------------------

Data from appropriate studies were pulled out independently by authors and potted into a spreadsheet. Inconsistencies were resolved by unanimity. The data extracted included (1) first author, location, and study design characteristics; (2) procedure characteristics and number, mean age, and gender of patients; (3) methods for screening of nasal *S. aureus* colonization, and strategies for decolonization for nasal MRSA carriers; (4) types of surgery and SSIs; (5) total numbers of *S. aureus* patients and non-colonized patients according to the results of nasal swab examination and the number of patients with SSIs in each group after surgeries. Study quality evaluation was performed with the Cochrane risk of bias tool \[[@CR11]\] which includes allocation concealment, blinding, outcome assessment, loss to follow-up (attrition), and the extent of imbalance of the study arms at the beginning of the trial.

Statistical analyses {#Sec6}
--------------------

We performed a meta-analysis to estimate pooled relative risks (RRs) and 95% confidence intervals (CIs) in STATA version 13.0 (StataCorp, College Station, TX, USA). Heterogeneity was assessed by the I^2^ statistic, for which an I^2^ \> 50% suggested substantial heterogeneity and vice versa. In this, I^2^ values of \< 25%, 25--50%, 50--75%, and \> 75%, were suggestive of low, moderate, substantial, and considerable heterogeneity, respectively. The effects model was chosen according to the heterogeneity. If the I^2^ was ≤ 50%, fixed effect model should be applied while I^2^ \> 50% random effect model should be applied. Furthermore, visual assessment of publication bias was shown using the funnel plot. In our study, p \< 0.05 was considered a significant difference.

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

The study selection process is presented in Fig. [1](#Fig1){ref-type="fig"}. A total of 1271 relavent studies were searched. 681 studies were subjected to abstract review, excluding many reviews, letters, conference abstracts, editorials and laboratory studies. The remaining 30 studies were subjected to full-text review to exclude those with irrelevant subjects or those that did not fully meet the inclusion criteria. Ultimately, 20 studies were included in the meta-analyses \[[@CR12]--[@CR31]\].Fig. 1Flow chart

Study characteristics and quality assessment {#Sec9}
--------------------------------------------

The characteristics of the included studies are presented in Table [1](#Tab1){ref-type="table"}. The studies were published between 1996 and 2019 and performed in the United States \[[@CR14], [@CR17], [@CR18], [@CR21], [@CR24], [@CR26]\], Netherlands \[[@CR16], [@CR28]--[@CR30]\], and Australia \[[@CR19], [@CR23], [@CR31]\]. Besides, the quality of included articles according to Cochrane's Book was shown in Fig. [2](#Fig2){ref-type="fig"}.Table 1Characteristics of the included studiesFirst authorYearCountryDesignTypes of surgeryNumberAgeIntervention1Akira2006JapanRCTEndoscopic gastrostomy4873--74Mupirocin, arbekacin, and sulfamethoxazole/trimethoprim vs untreated2Xavier2018GermanyRCTLung cancer surgery45049--9Chlorhexidine gluconate (CHG) vs placebo3Laura2014AmericanRCTLung cancer surgery36555.5--77.9Chlorhexidine vs untreated4Guy2016IsraelRCTCesarean section56826.8--37.4Mupirocin vs control5Albertine1998NetherlandsRCTOrthopedics10018 vs 10Mupirocin vs control6Michael2014AmericanRCTArthroplasty or spine fusion169719.1--93.2Mupirocin vs iodine7Nalini2008AmericanRCTJoint arthroplasty1377NAMupirocin vs TJA8Helena2018AustraliaRCTDermatological closures14255.2--77.4Cephalexin vs placebo9Saleh2016SwedenRCTDermatological closures4045-92PHMB-based solution vs sterile water10Shuman2012AmericanRCTHead and neck surgery8457.5--58.14Topical antimicrobial decolonization vs standard prophylaxis alone11Talesh2017IranRCTHead and neck surgery4419.7--45.3Mupirocin vs untreated12Yee2013Australia.RCTMohs micrographic surgery73864--67Mupirocin vs untreated13Berg2004AmericanRCTCardiac surgery29654.4--72.2Clarithromycin vs placebo14Konvalinka2006CanadaRCTCardiac surgery25751.7--73.3Mupirocin vs placebo15Zibari1997AmericanRCTThrombectomized grafts surgery40817--81Vancomycin vs not vancomycin16Andenaes1996NorwayRCTOrthopedics33924Azithromycin vs placebo17Bode2016NetherlandsRCTCardiac surgery793NAMupirocin vs placebo18Kalmeijer2002NetherlandsRCTOrthopedics61448.1--77.3Mupirocin vs placebo19Kluytmans1998NetherlandsRCTLung cancer surgery816NAChlorhexidine vs placebo20Smith2019AustraliaRCTMohs micrographic surgery135051--81Mupirocin vs untreatedFig. 2The quality assessment of included articles

Nasal decolonization and the risk of overall SSIs after surgery {#Sec10}
---------------------------------------------------------------

The pooled results from 20 studies \[[@CR12]--[@CR31]\] accounting of 10,526 patients showed that nasal decolonization may be associated with a significantly decreased risk of overall SSI in patients after surgery (RR = 0.59, 95% CI 0.38--0.90; Fig. [3](#Fig3){ref-type="fig"}). Random effects model was chosen to balance the statistical heterogeneity (p for Cochrane's Q test = 0.000, I^2^ = 75.8%). Thus, further subgroups analyses were posed to illustrate specific relationships.Fig. 3Nasal decolonization and the risk of overall SSI after surgery

Nasal decolonization and the risk of SSIs after orthopedics surgery {#Sec11}
-------------------------------------------------------------------

Three articles \[[@CR16]--[@CR18]\] with 3174 patients reported the SSIs and orthopedics surgery, showing that there was no statistical difference (RR = 0.68, 95% CI 0.16--2.82; Fig. [4](#Fig4){ref-type="fig"}). The substantial heterogeneity (p for Cochrane's Q test = 0.009, I^2^ = 78.8%) was demonstrated with analysis of random model.Fig. 4Nasal decolonization and the risk of SSI after orthopedics surgery

Nasal decolonization and the risk of SSIs after cardiovascular surgery {#Sec12}
----------------------------------------------------------------------

Four studies \[[@CR24]--[@CR28]\] enrolled 1754 patients comparing the decolonization in cardiovascular surgeries. No statistical difference was detected in the meta-analysis (RR = 0.33, 95% CI 0.08--1.35; Fig. [5](#Fig5){ref-type="fig"}). Statistical heterogeneity (p for Cochrane's Q test = 0.000, I^2^ = 86.0%) was handled in random model.Fig. 5Nasal decolonization and the risk of SSI after cardiovascular surgery

Nasal decolonization and the risk of SSI after pulmonary surgery {#Sec13}
----------------------------------------------------------------

Pooled estimates from three studies \[[@CR13], [@CR14], [@CR30]\] presented that nasal decolonization related to a significantly decreased risk of SSI in patients after pulmonary surgery (RR = 0.47, 95% CI 0.30--0.73; Fig. [6](#Fig6){ref-type="fig"}). Moreover, no significant heterogeneity was detected (p for Cochrane's Q test = 0.20, I^2^ = 37.9%).Fig. 6Nasal decolonization and the risk of SSI after pulmonary surgery

Nasal decolonization and the risk of SSI with different interventions {#Sec14}
---------------------------------------------------------------------

The interventions of decolonization were diverse, showing that 50% used mupirocin, 15% used chlorhexidine, 30% used different types of antimicrobial drugs, and 5% use others. As for that, ten articles comparing mupirocin with untreated administration, no significant difference was concluded (RR = 0.87, 95% CI 0.54--1.39; Fig. [7](#Fig7){ref-type="fig"}), while the heterogeneity was detected and balanced through random model (p for Cochrane's Q test = 0.33, I^2^ = 67.9%). However, there was a decreased risk of SSI in patients after chlorhexidine, with statistical difference (RR = 0.45, 95% CI 0.28--0.72; Fig. [8](#Fig8){ref-type="fig"}), and no significant heterogeneity was detected (p for Cochrane's Q test = 0.22, I^2^ = 33.8%).Fig. 7Nasal decolonization and the risk of SSI with mupirocinFig. 8Nasal decolonization and the risk of SSI with chlorhexidine

Publication bias {#Sec15}
----------------

Funnel plots for the associations between nasal *S. aureus* decolonization and overall SSI risks were shown in Additional file [2](#MOESM2){ref-type="media"}: Appendix S2. The funnel plots were symmetric on visual inspection.

Discussion {#Sec16}
==========

Our systematic review has identified important gaps in the literature on targeted decolonization strategies in *Staphylococcus aureus* carriers with different types of surgery. The overall SSIs and pulmonary surgery SSIs presented with a statistical difference in measures of nasal decontamination.

In an early meta-analysis of two randomized trials in cardiac surgery patients, limited by the number of studies, the results showed that no clear difference in SSI risk following the use of mupirocin compared with placebo (RR 1.60, 95% CI 0.79 to 3.25) \[[@CR9], [@CR25]\]. Moreover, a recent meta-analysis \[[@CR32]\] reported that nasal MRSA colonization may be associated with increased risks of overall SSI and MRSA-SSI after spine surgeries through seven studies (RR = 2.52 and 6.21, respectively, both p \< 0.001). Furthermore, a prospective, randomized, single-blinded trial, mentioned about SSIs after elective orthopedic surgery, found that no difference in the risk of SSI between the decolonization and control groups in 1318 patients, both in *S. aureus* carriers and non-carriers \[[@CR33]\]. Different results could also be found in another RCT \[[@CR3]\], Huang et al. found decolonization with universal chlorhexidine bathing and targeted mupirocin for MRSA carriers did not significantly reduce multidrug-resistant organisms in non-critical-care patients. In light of this, more prospective, randomized-controlled, multi-center studies were needed to articulate the relationships among them.

Trojan Horse \[[@CR34]\] claimed a hypothesis trying to explain SSI pathogenesis, showing that pathogens remote from the SSI area---such as within the teeth, noses, or gastrointestinal tract---can be taken up by immune cells (macrophages or neutrophils) and travel to the wound site where they cause wound infections. This mechanism could be verified in a mice model, which can also explain why some infections occur latently following surgery and are due to organisms not found in the wound at the end of the operation \[[@CR6], [@CR35]\].

Several limitations derived from this systematic review must be acknowledged. First, the number of included randomized studies was small, which prevented us from evaluating the potential influences of strains of *S. aureus* (e.g. hospital-associated MRSA/MSSA, community-associated MRSA/MSSA) on the association between nasal *S. aureus* colonization and SSIs events. In addition, some studies involved in this study are in high risk and high heterogeneity, which might result in inevitable bias. Last but not least, the adverse effects of decolonization (e.g. increased risk of drug resistance) had been merely mentioned, which is significant for an appliance.

To conclude, the main pillars of from available evidence, it seems that nasal decontamination may be associated with a reduction of overall SSIs in patients with pulmonary surgery or treated with chlorhexidine. Further studies are needed to validate and propose the specific relationships between host and infection.
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**Additional file 1.** Search strategy.

###### 

**Additional file 2.** Funnel plot.
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